Pharmaceuticals News and Research

RSS

GW Pharmaceuticals to expand marketing authorization for Sativex to France

GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that it has submitted an application under the European Mutual Recognition Procedure seeking to expand the marketing authorization for Sativex into France for the treatment of spasticity due to Multiple Sclerosis.

22 Jul 2013

Moberg Pharma granted exclusive rights to market Kerasal Nail in China

Moberg Pharma AB today announced that Menarini Asia-Pacific, a member of the Menarini Group - a top 40 global pharmaceutical company - has been granted the exclusive rights to market and sell Kerasal Nail in China. The companies now intend to seek marketing authorization for the product in the Chinese market.

22 Jul 2013

Bacillus-derived Hyaluronic acid from Novozymes Biopharma, Hyasis®, increases in vitro drug release time from under 10 minutes to approximately 15 hours

An investigation undertaken by Novozymes Biopharma DK has shown that when the corticosteroid dexamethasone is formulated in a cross-linked Hyaluronic acid (HA) hydrogel, the drug’s in vitro release time increases from under 10 minutes to approximately 15 hours. In addition, the in vivo half-life of dexamethasone is shown to plateau with stable dexamethasone concentration up to four hours after injection.

22 Jul 2013

Scientists to explore student-driven research model for Distributed Drug Discovery

Purdue University Indianapolis (IUPUI) will host scientists from around the world next week for the first-ever workshop devoted to Distributed Drug Discovery, an innovative, student-driven research program quickly becoming a high-impact, low-cost teaching model.

20 Jul 2013

Kala Pharmaceuticals to present preclinical data on mucosal-penetrating particle technology

Kala Pharmaceuticals, Inc., a leading developer of innovative products that rapidly and effectively penetrate the mucosal barrier to treat ocular diseases, announced today that Kala researchers will present preclinical data at the upcoming Controlled Release Society (CRS) 2013 Annual Meeting taking place July 21-24, 2013, in Honolulu, HI.

20 Jul 2013

CETSA helps scientists determine effectiveness of drugs in the body

The search for new drugs, including those for cancer, is set to speed up thanks to a new research technique invented by scientists at the Nanyang Technological University.

20 Jul 2013

Researchers demonstrate that 2-drug combination can eliminate cancer

New research conducted by Harvard scientists is laying out a roadmap to one of the holy grails of modern medicine - a cure for cancer.

20 Jul 2013

Pi2 Solutions introduces Drug Safety Triager application in UK

Pi2 Solutions introduces its Drug Safety Triager application to a wide UK audience of Drug Safety and Medical Information professionals at the 8th Annual Conference of the Pharmaceutical Information and Pharmacovigilance Association in Chesham, England.

20 Jul 2013

UCSF researchers find a way to knock down cancers caused by tumor-driving protein

UC San Francisco researchers have found a way to knock down cancers caused by a tumor-driving protein called -myc,- paving the way for patients with myc-driven cancers to enroll in clinical trials for experimental treatments.

20 Jul 2013

Tianyin Pharmaceutical provides further updates on Gingko Mihuan Oral Liquid

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and active pharmaceutical ingredients today provided further updates on the business development of its flagship product: Gingko Mihuan Oral Liquid with the SFDA approval number: H20013079.

19 Jul 2013

UCSF researchers find way to knock down cancers caused by myc protein

UC San Francisco researchers have found a way to knock down cancers caused by a tumor-driving protein called "myc," paving the way for patients with myc-driven cancers to enroll in clinical trials for experimental treatments.

19 Jul 2013

Anacor presents Phase 3 safety and efficacy results of Tavaborole for treatment of onychomycosis

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that its abstract "Pivotal Phase 3 Safety and Efficacy Results of Tavaborole (Formerly AN2690), a Novel Boron-Based Molecule for the Topical Treatment of Toenail Onychomycosis" was accepted for oral presentation at the 2013 APMA Annual Scientific Meeting (The National) to be held in Las Vegas, Nevada.

19 Jul 2013

WuXi buys Provantis Portal Remote Study Monitoring solution from Instem

Instem, a leading provider of IT solutions to the global early development healthcare market, announced today that WuXi AppTec, a leading supplier of R&D services to the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, has purchased the Provantis Portal Remote Study Monitoring solution.

19 Jul 2013

Cubist initiates bevenopran Phase 3 studies in patients with chronic non-cancer pain and OIC

Cubist Pharmaceuticals, Inc. today announced the initiation of Phase 3 efficacy studies of bevenopran (previously known as CB-5945) in patients with chronic non-cancer pain and opioid-induced constipation.

19 Jul 2013

Idera Pharmaceuticals receives patent related to IMO-8400

Idera Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office has issued to Idera patent number 8,486,908, providing both composition of matter and method of use protection for IMO-8400.

19 Jul 2013

FDA grants orphan drug designation to ARMAGEN's AGT-182 for treatment of Hunter syndrome

ARMAGEN announced today that the U.S. Food and Drug Administration has granted orphan drug designation to its lead product AGT-182 for the treatment of mucopolysaccharidosis type II (also known as Hunter syndrome or MPS II).

19 Jul 2013

HemoShear announces milestone in development of predictive drug safety systems

HemoShear, LLC, a leading developer of human-relevant systems for drug development and discovery, today announced an important milestone in the development of systems that predict safety of new drugs and chemicals.

19 Jul 2013

Par Pharmaceutical receives final ANDA approval for generic version of Trilipix

Par Pharmaceutical Companies, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for fenofibric acid EQ 45 mg and EQ 135 mg delayed-release capsules.

19 Jul 2013

Bausch + Lomb obtains option to license MIM-D3 for treatment of dry eye syndrome

Bausch + Lomb, the global eye health company, and Mimetogen Pharmaceuticals Inc. today announced that Bausch + Lomb has acquired an option to license an investigational compound currently in Phase 2 development for the treatment of dry eye syndrome, a condition that affects millions of people worldwide.

19 Jul 2013

Aquavit Pharmaceuticals signs licensing agreement with U-Bio Med for microneedle technology

Aquavit Pharmaceuticals, Inc. announces it has signed a definitive licensing agreement with U-Bio Med Inc., a medical technology device company in South Korea, for the worldwide commercialization of the company's microneedle device technology.

19 Jul 2013

Pharmaceuticals News and Research

GW Pharmaceuticals to expand marketing authorization for Sativex to France

Moberg Pharma granted exclusive rights to market Kerasal Nail in China

Bacillus-derived Hyaluronic acid from Novozymes Biopharma, Hyasis®, increases in vitro drug release time from under 10 minutes to approximately 15 hours

Scientists to explore student-driven research model for Distributed Drug Discovery

Kala Pharmaceuticals to present preclinical data on mucosal-penetrating particle technology

CETSA helps scientists determine effectiveness of drugs in the body

Researchers demonstrate that 2-drug combination can eliminate cancer

Pi2 Solutions introduces Drug Safety Triager application in UK

UCSF researchers find a way to knock down cancers caused by tumor-driving protein

Tianyin Pharmaceutical provides further updates on Gingko Mihuan Oral Liquid

UCSF researchers find way to knock down cancers caused by myc protein

Anacor presents Phase 3 safety and efficacy results of Tavaborole for treatment of onychomycosis

WuXi buys Provantis Portal Remote Study Monitoring solution from Instem

Cubist initiates bevenopran Phase 3 studies in patients with chronic non-cancer pain and OIC

Idera Pharmaceuticals receives patent related to IMO-8400

FDA grants orphan drug designation to ARMAGEN's AGT-182 for treatment of Hunter syndrome

HemoShear announces milestone in development of predictive drug safety systems

Par Pharmaceutical receives final ANDA approval for generic version of Trilipix

Bausch + Lomb obtains option to license MIM-D3 for treatment of dry eye syndrome

Aquavit Pharmaceuticals signs licensing agreement with U-Bio Med for microneedle technology

A guide to density measurement excellence eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence